The specialized AAV gene therapy company for treating incurable diseases
Developing “First-in-Class” gene therapies for incurable diseases.
ICM was established in 2012 as a subsidiary of Yonsei Technology Holdings.
Offers the prospect of disease modifying treatment by delivering therapeutic gene to target tissues.
